Antihyperlipidemic statins: A self-contained, clinically relevant medicinal chemistry lesson

American Journal of Pharmaceutical Education

Volumn 69, Issue 4, 2005, Pages 546-560

  Roche, Victoria F ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dyslipidemia; Hyperlipidemia; Medicinal chemistry; Statins

Indexed keywords

EID: 27744593677     PISSN: 00029459     EISSN: 15536467     Source Type: Journal    
DOI: 10.5688/aj690477     Document Type: Article

References (30)

1. Roche VF. Utilizing chemical knowledge in rational therapeutic decision-making. Am J Pharm Educ. 1985;49:154-7.
2. Roche VF. The use of case studies in medicinal chemistry instruction. Am J Pharm Educ. 1993;57:436-9.
3. Roche VF, Alsharif NA. Stayin' alive: advancing medicinal chemistry by enhancing student responsibility for learning. Am J Pharm Educ. 2002;66:319-28.
4. Alsharif NZ, Theesen KA, Roche VF. Structurally-Based Therapeutic Evaluation: A therapeutic and practice approach to teaching medicinal chemistry. Am J Pharm Educ. 1997;61:55-60.
5. Alsharif NZ, Roche VF, Ogunbadeniyi AM, Chapman RE. Evaluation of performance and learning parity between two required on-campus and Internet-based medicinal chemistry courses. Am J Pharm Educ. 2005;68:Article 33.
6. Roche VF, Zito SW. Computerized medicinal chemistry case studies. Am J Pharm Educ. 1997;61:447-52.
7. Roche VF, Aitken M, Zito SW. Evaluation of computerized medicinal chemistry case study modules as tools to enhance student learning and clinical problem-solving skills. Am J Pharm Educ. 1999;63:289-95.
8. Harrold M. Antihyperlipoproteinemics and inhibitors of cholesterol biosynthesis. In: Williams DA, Lemke TL, eds. Foye's Principles of Medicinal Chemistry. 5th ed. Baltimore, MD: Lippincott Williams & Wilkins;2002:580- 603.
9. Istvan ES, Deisenhofer J. The structure of the catalytic portion of human HMG-CoA reductase. Biochim Biophys Acta. 2000;1529:9-18.
10. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292:1160-4.
11. Laufs U. Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med. 2000;19:143-8.
12. Knapp AC, Huang J, Starling G, Kiener PA. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis. 2000;152:217-27.
13. Kassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Ab42 and Ab40 in vitro and in vivo. Proc Natl Acad Sci. 2001;98:5856-61
14. Moghadasian MH. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci. 1999;65:1329-37.
15. Evans M, Roberts A, Rees A. Pharmacological management of hyperlipidemia. Br J Diabetes Vasc Dis. 2003;3:204-10.
16. Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J. 2000;139:577-83.
17. Gotto AM Jr. Statin therapy: Where are we? Where do we go next? Am J Cardiol. 2001;87:13B-18B.
18. Brown WV. Novel approaches to lipid lowering: What is on the horizon? Am J Cardiol. 2001;87:23B-27B.
19. McTaggart F, Buckett L, Davidson R., et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87:28B-32B.
20. Olsson AG. Statin therapy and reduction in low-density lipoprotein cholesterol: Initial clinical data on the potent new statin rosuvastatin. Am J Cardiol. 2001;87:33B-36B.
21. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl. 2003;4:9-14.
22. Garcia MJ, Reinoso RF, Sanchez-Navarro A, Prous JR. Clinical pharmacology of statins. Meth Find Exp Clin Pharmacol. 2003;25:455-79.
23. Hatanaka T. Clinical pharmacokinetics of pravastatin. Drug Disposition. 2000;39:397-412.
24. Worz CR, Bottorff M. Treating dyslipidemic patients with lipid-modifying and combination therapies. Pharmacotherapy. 2003;23:625-37.
25. Stein EA. The power of statins: aggressive lipid lowering. Clin Cardiol. 2003;4:25-31.
26. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;165:553-64.
27. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother. 2001;35:908-17.
28. Portoghese PS, Sultana M, Nagase H, Takemori, AE. Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists. J Med Chem. 1988; 31:281-2.
29. Lipkowski AW, Tam SW, Portoghese PS. Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem. 1986;29:1222-5.
30. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264:71-5.